Member Info for smithy2014

Thank you Bakky, I appreciate that.

JAdam, I’ve not read this board for a week so I’m catching up and I was disappointed to read your comment about my post regarding the FT advert being bull. I heard about the advert in the first instance from someone else on this board, so I went out and bought the FT, came back home and relayed a very detailed description because obviously we can’t post photos. Sounds like you’ve spoke to Caxton now so I presume you confirmed the advert with them.

I can confirm that is the case. It’s a 29cm x 10cm size advert, which is a 3rd of the page height Under the FT header and stands out extremely well. It’s helped by the fact it’s a very uncluttered FT Money page. It’s got Yourgene and Caxton logos in each of the corners and then in huge text states ‘COVID-19 workplace testing’ and then underneath that in smaller but still big text compared to anything else, says ‘Reopen and stay open. Manage Coronavirus risk in your workplace with our managed antigen testing service with Yourgene Health. For more information, visit www.caxtonfx.com/covid19. Underneath that and very relevant is their registered office address: 30 St Marys Axe, London EC3A 8BF, which is the Gherkin in London so it’s very clear they are going hard at the big corporates in the city with money and a lot to lose by not operating.

No mention of the passport element but then a good advert is a simple advert and channels potential customers through the right door, which this does effectively, through a familiar name in the city.

Great to see this kind of aggressive marketing.

I have them on the Walbrook document from August 2019. I think they sent it to me via email from memory and would have also sent it to anybody who was registered to receive RNS updates from Yourgene, prior to them taking over their PR. I presume the link will still be on the Walbrook Twitter feed. I’ve never used Sharecast but these figures feed in from the two analysts who work with Yourgene but just to reiterate, they are the combined projections, not the individual broker forecasts, so figures elsewhere may differ very slightly depending if they are using Stifel, Singer or both combined.

I have just been chatting with Paul who is the MD at Walbrook, in relation to available equity analyst research in the market for Yourgene. Stifel and N+1 Singer are the analysts that work with Yourgene but their research is only available to their institutional clients and will be updated after the full year results in mid July and will reflect new broker targets, as referenced by Florida.

Last year in August, Walbrook issued a high level summary of the consolidated key figures that Stifel and N+1 Singer arrived at in their updated research, and included Full Year Revenue, EBITDA and Profit Before Tax projections for Year End 2020, 2021, and 2022 and they are planning to do the same this August. This will be issued via their Twitter page so retail investors can see them. However, please note that the three month unaudited figures from March that will be included in the new broker calculations will obviously only include the Covid manufacturing for Novacyt in addition to the core business, so don’t expect a significant uplift in those projected Year End figures for 2021 and 2022 at this stage. We won’t know until the half year trading update in September, what the true impact of our new products (that have not launched yet) will be. Below is the previously issued projections for 2021/22 so people have an overview:

Full Year 2021
Sales 21.3
EBITDA 3.8
PBT 1.4

Full Year 2022
Sales 25.7
EBITDA 5.8
PBT 3.5

In summary, we will not have Year End 2021 projections along with the financial results in mid July, so I think it’s important people understand this so expectations are managed.

On a separate note, I have always found the Hardman report (previously issued in February the last couple of years) particularly informative as an investor, so I asked Paul about this. He was not aware of that being in the pipeline but it was last issued before Walbrook took over management of the PR, so he is going to feed this into Yourgene, so hopefully that may surface again in the future

Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a collaboration agreement with international payments company Caxton and immunity passport app Prova, which once launched will support the efforts to get Britain back to work by testing employees for COVID-19.
The collaboration with Prova and Yourgene will enable Caxton to offer COVID-19 tests to its extensive network of corporate clients and their employees. The immunity passport app Prova, created by London-based Hooha
Innovations, enables employees to download and request a COVID-19 test. Once a test sample has been taken and the sample processed, the results will be automatically delivered securely to the Prova app, allowing the user to
share and prove their COVID-19 status without revealing any personal information.
Yourgene’s responsibilities will lie in providing the clinical and technical expertise, by providing sample collection kits, training a healthcare professional to take the sample safely and effectively then running the COVID-19 test in its Manchester Citylab facility. The collaboration will use the Company’s ClarigeneTM SARS CoV-2 CE-IVD assay when
launched and the patient results will be uploaded securely to the Prova app.
As announced on the 26 May 2020, the Company is still on track to release a ‘Research Use Only’ version of Clarigene SARS-CoV-2 test by the end of June 2020 and achieve a CE marked in vitro diagnostic kit to follow in July
2020.
Lyn Rees, CEO of Yourgene, commented: “We are proud to support this effort as the COVID-19 lab partner to this collaboration, working with Caxton and Prova, enabling employees to return to work safely. We look forward to updating the market as the project progresses as we expect to launch in Summer 2020.”
Rupert Lee-Browne, CEO of Caxton comments: “Getting Britain back to work is vital for the economy and we are pleased to be able to offer this unique service of test and verify to Caxton’s business clients. We chose Yourgene because they match our own values around product quality and reputation and we look forward to helping our customers with this easy solution to creating safe work spaces.”
Ed Keohane, CEO of Hooha, creators of the Prova app, comments: “We are delighted to be integrating Yourgene Health’s high-quality COVID-19 tests to automatically deliver results to Caxton’s business customers as part of Back to Work, allowing them to share and prove their COVID-19 health status without revealing any personal information.”

I guess that’s definitely possible Seaview and whilst I did find something online regarding testing of swine flu within the equine community historically, I was thinking more about a general suite of products for animals longer term. We have a set of products for humans and people love their pets dearly and spend a lot of money on them, so why wouldn’t they potentially want to have an option to test for A, B, C etc.

Incidentally, when I was looking at Lyns profile on the website it specifically mentions that he established BBI Animal Health with his previous employer. I hadn’t even considered animals as a potential target market for our products but if he’s done it before and it mentions it on his bio, you would think that this must be sitting on a list with their R&D department for the future. I can’t wait to see what this business looks like in a few years time, I think we’ll all be surprised at how big and diverse it gets.

Thanks Bakky, that’s a really interesting article.

I can’t see it myself, it feels that with our current operation there, we would be too small and would be too late to the party but you never know with Lyn, theres always a potential rabbit in the hat. What it did highlight to me is just how big the opportunity could be for our new product suite across our other territories where we do have solid established networks, particularly Asia Pacific where the population is vast. I did a bit of research after reading the article and found that Australia as one example, typically test hundreds, if not thousands of individuals on the back of one positive Covid test being done within their track and trace programme. That certainly gave me something to think about with my coffee this morning.

On a separate subject, China was talked about (I think in last years final results maybe) as a target market. I know its very challenging in terms of regulatory hurdles there but for me, entry into China be it through acquisition or new entity set up, would be game changing with their population. I’m keen to see if that’s mentioned in the end of year results. I did a bit of digging and Lyn establishes an entity in China in his last role, so he’s got previous there and we have our base in Taipei. Food for thought.

Come on twix, surely you can be honest enough with yourself and admit that you do clearly care what people think. Why else do you tell everyone when you are buying and when you are selling and at what price. I also note that when Florida incorrectly suggested that you trade £100,000 per day, when you actually trade up to 100,000 shares per day (according to your posts) you let that ride, whilst answering his other points. Let’s not pretend you didn’t like that and that’s why you kept quiet instead of correcting him ;)

Let’s put this in perspective for the newbies who haven’t been around long enough to experience your posting habits and seem to think you’re significantly influencing the share price movement - twix holds/held 2,000,000+ shares recently according to his post and the company has 616,482,205 in circulation. I don’t care much for your trading posts but I really do care passionately when other individuals on this board are potentially being mislead and I find it incredibly shallow when grown men can’t be honest with themselves. For anyone overly interested in his share trading, I suggest you ignore it and focus on the other positive and factually accurate rhetoric on here from individuals like like flipper, cooper and steve67.

Twix, my point is that if the Novacyt Labs are officially going on stream next week as per the statement in the Daily Briefing, then maybe an opportunity for Yourgene to update the market on some sort of testing manufacturing numbers, will present itself moving forward. One would assume that the numbers will be increasing rapidly from that point onwards for Novacyt to get to 288k per week for the U.K. government (not day as I’m i mentioned previously).

Daily briefing gives a very interesting snippet.....Matt Han**** talks about who is supporting the testing effort and specifically mentions “Novacyt who’s labs go on stream next week”.

Their agreement with the government is to supply 288,000 tests per day from a June I think, from memory of the article earlier this week. We are one of 5 manufacturing partners supporting them in the UK I believe so there should be good revenue generation in the coming months, in addition to the core business and the other very exciting news we are patiently waiting for re accreditation etc.

Lots to be excited about for the future.

New Lyn Rees business update interview has just been posted on the Yourgene twitter feed.

I can see that there are 6 roles being advertised by Yourgene at the moment, which is a great sign because these are new roles to support growth. Senior Clinical Sales Manager in Singapore covering Asia Pacific is a good addition and specifically mentions Australia & New Zealand as being a key focus moving forward.

It certainly feels like we will be nudging 20p soon on current momentum Steve. No doubt a lot of bed & isa transactions being completed today, which is helping. Looking forward to some news headlines fro the webinar tomorrow and an imminent trading update.

I think like most other AIM shares, this was oversold during the initial panic but confidence is returning and will hopefully continue to do so. Personally, I consider this a ‘defence’; stock for hard times because ultimately, people will still continue to have babies. I actually think that the uptake of our tests could be impacted in a positive way when this crisis is out of the way because people may be scared by what is happening and want to do whatever they can to be best informed about anything that could impact their health.

Whilst common sense tells us that the current situation could impact sales for a few months, I think we should be very thankful that we already have a large geographical footprint established. Imagine if we were just selling into a handful of countries at this stage; that would be worrying. There may well be some smaller businesses ripe for acquisition on the other side of this. Lynn is a proven M&A guy and bought and integrated over 8 companies with his last employer so this is what he will no doubt aim to do again.

Interesting but still exciting times ahead in my personal opinion.

https://www.valuethemarkets.com/2020/03/04/first-profits-and-market-conditions-make-yourgene-a-buy-ygen/

That’s a very good point you make about the pricing Chris. I too am down a very significant chunk on paper, so it’s nice to remind myself of the true market potential long term and remove the insatiable urge to focus on the current SP on a daily basis. Patience will be rewarded by mid Jan I would hope.

I thought this was quite an informative read about food security for the expected growth in population in Asia over the next 10 years. One would hope that the market for products like Poly4 will just get stronger and stronger over the next 5-10 years, bang in line with the planned ramp up to 20 mtpa.

https://www.cnbc.com/2019/11/27/asias-food-crisis-a-800-billion-investment-needed-in-next-10-years.html

There is absolutely no need for that attitude Chriskies, I was simply trying to provide something that will help some nervous individuals better understand the situation surrounding communication.

I don’t believe it implies that, simply that they don’t need to tell us via an RNS.